QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
- 9 January 2023Portfolio NewsTRexBio Announces Collaboration and License Agreement with Lilly to Develop and Commercialize Novel Therapies for Immune-Mediated Diseases
- 9 January 2023Portfolio NewsExclusive: Eli Lilly boosts inflammatory disease pipeline, licenses three candidates from TRexBio
- 5 January 2023Portfolio NewsQurAlis Announces First-in-Human Dose in Phase 1 Clinical Trial of QRL-101, a First-in-Class Kv7 Precision Therapy for ALS
- 26 December 2022Portfolio NewsWhy a lucky few may help the rest of us beat disease
- 20 December 2022Portfolio NewsMestag Therapeutics appoints Prof. Ton Logtenberg as Chair
- 13 December 2022Portfolio NewsIn its largest single-asset purchase ever, Takeda snaps up TYK2 drug [from SV portfolio company, Nimbus] for $4B upfront
- 13 December 2022Portfolio NewsTakeda to Acquire Nimbus Therapeutics’ Highly Selective, Allosteric TYK2 Inhibitor to Address Multiple Immune-Mediated Diseases
- 13 December 2022Portfolio NewsDementia Discovery Fund invests in Amphista Therapeutics as it targets neurodegenerative diseases
- 8 December 2022Portfolio NewsQurAlis Receives Health Canada Clinical Trial Application Authorization for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS
- 6 December 2022Portfolio NewsAlison Burkland, co-founder of MCF portfolio company Nanopath, has been named one of Forbes' 30 under 30
- 5 December 2022Portfolio NewsNinerafaxstat Showcased at the 19th Annual Global Cardio Vascular Clinical Trialists (CVCT) Forum with Focus on the Potential in Non-obstructive Hypertrophic Cardiomyopathy
- 31 October 2022Portfolio NewsNitrase Therapeutics Presented Data on Role of Novel Nitrases in Regulating Known and Important Cancer Targets at EORTC-NCI-AACR Symposium